Study ID | Country | Sample source | Sample type | Cases/controls | Assay type | Kit provider | Mean resistin level (ng/ml) ± SD | NOS score | |
---|---|---|---|---|---|---|---|---|---|
Cases | Controls | ||||||||
Ahmed [40] | Iraq | Serum | Premenopausal | 90/90 | ELISA kit | Bio-Rad Laboratories | 18.32 ± 2.4 | 3.5 ± 0.5 | 7 |
Alokail et al. [41] | KSA | Serum | Both | 56/53 | ELISA kit | Immunodiagnoztik | 18.9 ± 1.2 | 15.2 ± 1 | 7 |
Aly et al. [42] | KSA | Serum | UD | 35/40 | ELISA kit | Invitrogen | 4.42 ± 4.74 | 1.84 ± 2.35 | 7 |
Assiri & Kamel [43] | KSA | Serum | Postmenopausal | 110/89 | ELISA kit | R&D systems | 26.24 ± 1.95 | 22.63 ± 3.99 | 8 |
Assiri et al. [44] | KSA | Serum | Both | 82/68 | ELISA kit | R&D systems | 26.24 ± 1.59 | 22.69 ± 2.58 | 8 |
Crisóstomo et al. [45] | Portugal | Serum | Both | 77/77 | ELISA kit | Duo Set ELISA | 14.58 ± 10 | 10.86 ± 8.55 | 8 |
Dalamaga et al. [46] | Greece | Serum | Postmenopausal | 102/102 | ELISA kit | Avibion | 11.2 ± 6.4 | 7.7 ± 4.85 | 8 |
Dalamaga et al. [47] | Greece | Serum | Postmenopausal | 103/103 | ELISA kit | Avibion | 11.24 ± 6.44 | 7.73 ± 4.85 | 8 |
Georgiou et al. [48] | Greece | Serum | Both | 157/52 | ELISA kit | BioVendor | 6.09 ± 3.08 | 6.16 ± 1.85 | 7 |
Gunter et al. [49] | USA | Plasma | Postmenopausal | 875/821 | ELISA kit | EMD Millipore | 12.1 ± 1.8 | 12.3 ± 1.933 | 8 |
Hou et al. [50] | China | Serum | Both | 80/50 | ELISA kit | R&D systems | 26.35 ± 5.36 | 23.32 ± 4.75 | 7 |
Kang et al. [51] | Korea | Plasma | Both | 41/43 | ELISA kit | AdipoGen | 5.23 ± 6.9 | 1.46 ± 2 | 8 |
Muñoz-Palomeque et al. [18] | Mexico | Serum | Postmenopausal | 20/40 | ELISA kit | Preprotech Kit | 10.60 ± 2.08 | 8.26 ± 2.38 | 7 |
Patrício et al. [52] | Portugal | Serum | Both | 64/52 | ELISA kit | Duo Set ELISA | 17.30 ± 12.6 | 11.60 ± 11.4 | 8 |
Wang et al. [53] | Taiwan | Serum | UD | 240/100 | ELISA kit | eBioscience | 32.72 ± 13.42 | 27.36 ± 5.49 | 7 |
Total | 2132/1780 |